Compare AbCellera Biologics Inc (ABCL) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.82. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | RDTE | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $34.73 |
52-Week Low | $2.78 | $26.40 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
RDTE trades at $29.33 with a slight 0.55% daily gain. Technical indicators show mixed signals with a neutral overall rating, while moving averages suggest a bullish bias. The stock has demonstrated consistent dividend payments throughout 2026, though key valuation metrics remain unavailable. Recent news highlights concerns about the ETF's structural risks and capital erosion potential despite high yield characteristics.
The outlook remains cautious given structural concerns about the covered call strategy's limitations. While regular dividends provide income appeal, the strategy's capped upside and full downside exposure present significant risk factors that may outweigh yield benefits for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
